Tolerance and Pharmacokinetics of TQB2450
NCT03460457 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2018-03-09
Summary
To study the pharmacokinetic characteristics of TQB2450 in the human body, recommend a reasonable regimen for subsequent research.
Conditions
- Tumor
Interventions
- DRUG
-
TQB2450
Pharmacokinetics/Dynamics Study
Sponsors & Collaborators
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-03-15
- Primary Completion
- 2019-03-15
- Completion
- 2019-03-15
More Related Trials
-
Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors
NCT05645315 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors
NCT07291050 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics
NCT02944864 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule
NCT04275583 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors
NCT04128085 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets
NCT04481607 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors
NCT04975204 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor
NCT05021367 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 Tablets
NCT04408079 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
NCT06413953 ·Status: RECRUITING ·Phase: PHASE1
-
A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer
NCT06344351 ·Status: COMPLETED ·Phase: PHASE1
-
Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects
NCT05610202 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase I Study of TQB728 Tablets on Tolerance and Pharmacokinetics
NCT04523285 ·Status: UNKNOWN ·Phase: PHASE1
-
A New Drug Used for Advanced Cancer
NCT03447145 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors
NCT04830501 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics
NCT03019276 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor
NCT00921336 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer
NCT06415903 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer
NCT06165809 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors
NCT04623892 ·Status: UNKNOWN ·Phase: PHASE1
-
The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor
NCT04871347 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy
NCT06211751 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies
NCT04412577 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics
NCT03099330 ·Status: UNKNOWN ·Phase: PHASE1
-
Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors
NCT05489276 ·Status: UNKNOWN ·Phase: PHASE1